10X Genomics Inc reports results for the quarter ended in March - Earnings Summary

10x Genomics

30/04/2024 22:52

* 10X Genomics Inc  TXG.OQ  reported a quarterly adjusted
loss
of 50 cents​​ per share for the quarter ended in March, lower
than the same quarter last year, when the company reported EPS
of -44 cents.  The mean expectation of sixteen analysts for the
quarter was for a loss of 50 cents per share. Wall Street
expected results to range from -65 cents to -30 cents per share.
    * Revenue rose 5% to $141.01 million from a year ago;
analysts
expected $142.25 million. 
    * 10X Genomics Inc's reported EPS for the quarter was a loss
of 50
cents​.
    * The company reported a quarterly loss of $59.95 million.
    * 10X Genomics Inc shares had fallen by 24.3% this
quarter and
lost 49.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 11.7%
in the last three months.​ 
    * In the last 30 days, three analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for 10X Genomics Inc
is $53.50 
This summary was machine generated from LSEG data April 30 at
09:51 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.50          -0.50          Met
 Dec. 31 2023      -0.36          -0.41          Missed
 Sep. 30 2023      -0.46          -0.79          Missed
 Jun. 30 2023      -0.40          -0.53          Missed